APTX
Aptinyx Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate-rather than block or over-activate-NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson's disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders.
Market Cap: 6.77 Million
Primary Exchange: NASDAQ
Website: www.aptinyx.com
Shares Outstanding: 67.7 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.5641553696440997
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 1455 trading days
From: 2018-09-10 To: 2023-05-18
Lowest Point:
MNKD, DATA among premarket gainers
via: SeekingAlpha at 2019-06-10 05:13:59:000
Provention Bio (NASDAQ: PRVB ) +170% on potential of teplizumab to delay diabetes. More news on: Provention Bio, Inc., Tableau Software, Inc., Tilray, Inc., Stocks on the move, Read more … read more...
MNKD, DATA among premarket gainers
via: SeekingAlpha at 2019-06-10 05:13:59:000
Provention Bio (NASDAQ: PRVB ) +170% on potential of teplizumab to delay diabetes. More news on: Provention Bio, Inc., Tableau Software, Inc., Tilray, Inc., Stocks on the move, Read more … read more...
MNKD, DATA among premarket gainers
via: SeekingAlpha at 2019-06-10 05:13:59:000
Provention Bio (NASDAQ: PRVB ) +170% on potential of teplizumab to delay diabetes. More news on: Provention Bio, Inc., Tableau Software, Inc., Tilray, Inc., Stocks on the move, Read more … read more...
Aptinyx up 14% premarket on positive NYX-2925 data in fibromyalgia
via: SeekingAlpha at 2019-06-10 04:43:03:000
Thinly traded micro cap Aptinyx (NASDAQ: APTX ) is up 14% premarket on average volume in response to positive Phase 2 data on NMDA modulator NYX-2925 in 23 patients with fibromyalgia , a disorder characterized by widespread musculoskeletal pain. More news on: Aptinyx Inc., H… read more...
Aptinyx up 14% premarket on positive NYX-2925 data in fibromyalgia
via: SeekingAlpha at 2019-06-10 04:43:03:000
Thinly traded micro cap Aptinyx (NASDAQ: APTX ) is up 14% premarket on average volume in response to positive Phase 2 data on NMDA modulator NYX-2925 in 23 patients with fibromyalgia , a disorder characterized by widespread musculoskeletal pain. More news on: Aptinyx Inc., H… read more...
Aptinyx up 14% premarket on positive NYX-2925 data in fibromyalgia
via: SeekingAlpha at 2019-06-10 04:43:03:000
Thinly traded micro cap Aptinyx (NASDAQ: APTX ) is up 14% premarket on average volume in response to positive Phase 2 data on NMDA modulator NYX-2925 in 23 patients with fibromyalgia , a disorder characterized by widespread musculoskeletal pain. More news on: Aptinyx Inc., H… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|